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Natural killer (NK) cells are at the crossroad between
innate and adaptive immunity and play a major role in
cancer immunosurveillance. NK cell stimulation depends
on a balance between inhibitory and activating receptors,
such as the stimulatory lectin-like receptor NKG2D. To
redirect NK cells against tumor cells, we designed bifunc-
tional proteins able to specifically bind tumor cells and to
induce their lysis by NK cells, after NKG2D engagement.
To this aim, we used the ‘knob into hole’ heterodimeriza-
tion strategy, in which ‘knob’ and ‘hole’ variants were
generated by directed mutagenesis within the CH3 domain
of human IgG1 Fc fragments fused to an anti-CEA or
anti-HER2 scFv or to the H60 murine ligand of NKG2D,
respectively. We demonstrated the capacity of the bifunc-
tional proteins produced to specifically coat tumor cells
surface with H60 ligand. Most importantly, we demon-
strated that these bifunctional proteins were able to induce
an NKG2D-dependent and antibody-specific tumor cell
lysis by murine NK cells. Overall, the results show the
possibility to redirect NK cytotoxicity to tumor cells by a
new format of recombinant bispecific antibody, opening
the way of potential NK cell-based cancer immunothera-
pies by specific activation of the NKG2D receptor at the
tumor site.
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Introduction
Natural killer (NK) cells are cytotoxic cells, belonging to
innate immunity, which play a major role in host response
against different pathogens, such as viruses (Bukowski et al.,
1985), bacteria or parasites (Tay et al., 1998). It is also now
well established that NK cells are involved in cancer
immunosurveillance (Kim et al., 2000; Smyth et al., 2002).
Despite no expression of antigen-specific receptors, such as
T- or B-cell receptors (TcR and BcR), NK cells are able to
recognize infected or malignant cells by several inhibitory or
activating receptors, which act in balance either to induce
NK cell tolerance towards normal cells or to promote NK
cell activation and lysis of infected or tumor cells (Raulet
and Vance, 2006). While inhibitory receptors, such as the
killer immunoglobulin-like inhibitory receptors (KIR), are
able to recognize the classical major histocompatibility class
I (MHC I) proteins, whose expression is often lost or down-
regulated on infected (Lodoen and Lanier, 2005) or malig-
nant cells (Garrido et al., 1997), activating receptors, such as
the natural cytotoxicity receptors (NCR) NKp30, NKp44 and
NKp46 or the natural killer group 2 D (NKG2D) receptor,
are able to recognize different ligands over-expressed on
transformed cells (Moretta et al., 2001).
The activating NKG2D receptor has been particularly
studied, both in humans and in mice. It is homogeneously
expressed on all human and mouse NK cells (Bauer et al.,
1999; Jamieson et al., 2002), but also on all human and
mouse-activated CD8 þ T cells, where it acts as a TcR
co-activator (Groh et al., 2001; Jamieson et al., 2002).
Several NKG2D ligands are now well described. The human
NKG2D ligands comprise the MHC I chain-related proteins
A and B (MICA and MICB) (Bahram et al., 1994) and the
retinoic acid early transcripts (RAET1E, G, H, I, L, N)
[IMGT Repertoire (RPI); http://imgt.cines.fr] (Cosman et al.,
2001; Jan Chalupny et al., 2003). In mice, NKG2D ligands
include the minor histocompatibility antigen H60
(Malarkannan et al., 1998), the retinoic acid early transcript
1 molecules a, b, g, d and 1 (Rae1a–1) (Cerwenka et al.,
2000) and the murine UL16-binding protein-like transcript 1
molecule (Mult1) (Carayannopoulos et al., 2002). All these
ligands are stress-induced proteins and have been identified
on various tumor cell types, such as human epithelial carci-
nomas, melanomas, gliomas and leukemias (Pende et al.,
2002; Vetter et al., 2002; Friese et al., 2003; Salih et al.,
2003) or mouse epithelial carcinomas and lymphomas
(Cerwenka et al., 2000; Diefenbach et al., 2000;
Carayannopoulos et al., 2002). However, during tumor pro-
gression, malignant cells lose frequently NKG2D ligand
expression, as a consequence of tumor variant selection
(Vetter et al., 2004; Carbone et al., 2005), contact inhibition
(Zou et al., 2006) or proteolytic shedding (Salih et al., 2002;
Salih et al., 2003), and thus escape to NK cell recognition.
Several studies have established that transfection of human
tumor cells with genes encoding NKG2D ligands sensitizes
these cells to NK cell-mediated lysis in vitro, in an
NKG2D-dependent pathway (Friese et al., 2003; Busche
et al., 2006). It has also been demonstrated in vivo that trans-
fected murine tumor cells expressing Rae1 or H60 are
rejected by NK cells, while parental tumor cells critically
grow, and that rejection is associated with T cell response
priming (Diefenbach et al., 2001).
To bypass the need of a gene therapy, we designed here
bifunctional proteins able to bind tumor cells through specific
antibody structures and to coat tumor cell surface with
NKG2D ligands. These new bifunctional proteins were pro-
duced according to the ‘knob into hole’ strategy, which
allows the preferential heterodimerization of two heavy
chains of distinct origin by changing two amino acids in
their CH3 domains, and thus the production of recombinant
bispecific antibodies (Ridgway et al., 1996; Merchant et al.,
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1998). In the present study, we assembled through this strat-
egy two different anti-tumor-associated antigen (TAA) scFv
with the mouse NKG2D ligand H60. After showing the
specificity of these new bifunctional proteins for two targeted
TAAs, we demonstrated their capacity to stimulate
NKG2D-dependent tumor cell lysis by murine NK cells.
Materials and methods
Tumor cell lines
Human acute monocytic leukemia THP-1 [expressing Fc
receptors (FcR) FcgRI and FcgRII] and human breast carci-
noma SK-BR-3 (expressing HER2) were obtained from the
American Type Culture Collection (Rockville, MD, USA)
and maintained as described by the manufacturer. The
murine colon carcinoma MC38 expressing CEA
(C15.4.3.AP) cell line [kindly provided by Dr J. Primus,
Department of Pathology, Vanderbilt University Medical
Center, Nashville, TN, USA (Clarke et al., 1998)], the
murine melanoma B16 expressing HER2 cell line [kindly
provided by Dr A. Donda, Department of Biochemistry,
Faculty of Biology and Medicine, University of Lausanne,
Switzerland (Stirnemann et al., 2008)] and the murine T lym-
phoma RMA expressing CEA cell line, obtained by electro-
transfection (250 V, 960 mF, 5 mg of DNA) of RMA cells
with plasmid-containing human CEA cDNA (Pelegrin et al.,
1992), were maintained in DMEM/F12 (1:1) supple-
mented with 2 mmol/l L-glutamine, 10% fetal calf serum
(FCS), penicillin (100 units/ml)/streptomycin (100 mg/ml)
and geneticin (0.5 mg/ml; Life Technologies, Grand Island,
NY, USA).
Vectors construction
The sequences of the different primers used for the construc-
tion of the bifunctional proteins are given in Table I. First,
the genes encoding anti-human CEA scFv 511 (in pFLAG-1,
kindly provided by Dr A.V. Terskikh, The Burnham Institute
of Medical Research, La Jolla, CA, USA, derived from the
mouse anti-human CEA mAb 511 hybridoma) and anti-
human HER2 scFv 4D5 [in Bluescriptw II KS þ/2, kindly
provided by Dr Alena Donda, Department of Biochemistry,
Faculty of Biology and Medicine, University of Lausanne,
Switzerland, derived from the humanized anti-human HER2
mAb 4D5 (Deyev et al., 2003)] were amplified by PCR using
primers P1/P2 and P3/P4. The amplified fragments were next
digested and inserted in frame in plasmid ps878 (kindly
provided by Dr P. Schneider, Department of Biochemistry,
Faculty of Biology and Medicine, University of Lausanne,
Switzerland (Schneider, 2000)] encoding human IGHG1 Fc
fragment (hinge, CH2 and CH3; GenBank/EMBL/IMGT/
LIGM-DB accession No. X70421), with the signal sequence
of the influenza virus hemagglutinin (HA) to allow protein
secretion by mammalian cells. Knob variants of each con-
struction were obtained by site-directed mutagenesis
(PROMEGA Kit) in the IGHG1 CH3 sequence using
primers P5/P6 (Xie et al., 2005). Plasmid ps521-rH60-Fc
[kindly provided by Dr W. Held, Ludwig Institute for Cancer
Research, Lausanne branch, Switzerland (Coudert et al.,
2005)] contains the gene encoding the extracellular portion
including the endogenous leader peptide of H60 (amino
acids 1–213), amplified by polymerase chain reaction (PCR)
from A20 B-cell cDNA, using the following primers (restric-
tion sites are underlined): H60 50 sense, actg AAGCTT
tgagggaagacc ATG GCAAAG G; H60 30 antisense, actg
GTCGAC CTG GTT GTC AGA ATT ATG TCG GAA
G. The PCR product was directionally cloned into modified
PCR-3 vectors (Invitrogen, San Diego, CA, USA) to add a
COOH-terminal FLAG epitope or to generate an Fc fusion
protein (kindly provided by P. Schneider, Department of
Biochemistry, University of Lausanne, Switzerland). A hole
variant of this construction was obtained by site-directed
mutagenesis using primers P7/P8 (Xie et al., 2005).
Site-directed mutagenesis efficiency was verified by
sequencing.
Bifunctional proteins expression and purification
HEK 293 cells (ATCC CRL-1573) were grown in DMEM/
F12 (1:1) supplemented with 2 mmol/l L-glutamine, 10%
FCS and penicillin (100 units/ml)/streptomycin (100 mg/ml)
and transfected with each mutant vector using FuGene 6
reagent (Roche Applied Science, Indianapolis, IN, USA), as
recommended by the manufacturer. Clones were selected by
limit dilution with medium containing geneticin (0.8 mg/ml).
Culture supernatant of each clone was assayed for bifunc-
tional proteins production by western blotting, as below. As
control, HEK 293 cells were also transfected with the orig-
inal ps521-rH60-Fc vector encoding rH60-Fc, or with the
original ps878 vector, encoding (scFv 511)-Fc or (scFv
4D5)-Fc, or untransfected. For the production of homodi-
meric and bifunctional proteins, selected clones were cul-
tured for 12 days in medium without geneticin and FCS.
Supernatant of these production batches were purified by affi-
nity chromatography using a protein G column (Amerscham
Pharmacia Biotech AB, Uppsala, Sweden) according to the
manufacturer’s instructions, and by gel filtration on a 16/60
Superdex 200 L column (Amerscham Pharmacia Biotech
AB). Average yield of each of the recombinant proteins
produced were: 3, 5.5 and 1.5 mg/ml for rH60-Fc, (scFv
4D5)-Fc and (scFv 511)-Fc, respectively, and 2 and 4 mg/ml
for (scFv 511/rH60)-Fc and (scFv 4D5/rH60)-Fc, respectively.
A schematic representation of the different homodimeric and
bifunctional proteins produced is proposed in Fig. 1.
SDS–PAGE and western blot analyses of the produced
bifunctional proteins
Purified bifunctional proteins, namely (scFv 511/rH60)-Fc
and (scFc 4D5/rH60)-Fc, were analysed on a 6% SDS–
PAGE gel, in comparison with homodimeric control proteins,
Table I. Sequence of the different primers used for vector constructions
Primers Sequence (50!30) Note
P1 atactcgagctggaggagtctggggag anti-CEA scFv (scFv 511) 50
P2 acagtcgacgatctccagtttggtccca anti-CEA scFv (scFv 511) 30
P3 gagctcgaggactacaaagatatc anti-HER2 scFv (scFv 4D5) 50
P4 tccgtcgacagaagaaacggtaac anti-HER2 scFv (scFv 4D5) 30
P5 ggtcagcctgtactgcctggtcaa Fc knob variant T366Y 50
P6 cagtacaggctgacctggttc Fc knob variant T366Y 30
P7 caccagcaagctcaccgtgga Fc hole variant Y407T 50
P8 tccacggtgagcttgctggtgaggaagaa Fc hole variant Y407T 30
Underlined sequences represent XhoI and SalI restriction sites. Bold
sequences represent nucleotides modified in sequence encoding CH3 domain
of human IGHG1 Fc.
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rH60-Fc and (scFv 511)-Fc or (scFv 4D5)-Fc, under non-
reducing and reducing conditions. For western blot analysis,
reduced proteins were transferred to a nitrocellulose mem-
brane. The membrane was saturated for 2 h in PBS-0.1%
Tween 20 containing 5% non-fat dried milk at room temp-
erature under agitation, incubated after washing with a rat
anti-H60 mAb (R&D Systems Inc., Minneapolis, MN, USA)
and then with an HRP-conjugated goat anti-rat IgG whole
molecule mAb (Sigma Aldrich, St Louis, MO, USA), or
directly incubated with an HRP-conjugated goat anti-human
IgG Fc specific mAb (Sigma-Aldrich). Finally, membrane
was revealed after washing using the ECL western blotting
system (Amersham Pharmacia Biotech AB).
Flow cytometry analyses
TAAs and H60 expression on tumor cell lines was
assessed by flow cytometry with mouse anti-CEA 511 mAb,
humanized anti-human HER2 trastuzumab (Herceptinw,
Genentech, Inc., San Francisco, CA, USA) and a rat anti-
H60 mAb, revealed by a FITC-conjugated goat anti-mouse
IgG Fc specific mAb (Sigma-Aldrich), a FITC-conjugated
goat anti-human IgG Fc specific mAb (Sigma-Aldrich) or a
FITC-conjugated mouse anti-rat IgG2a Fc specific mAb (BD
Pharmingen, San Diego, CA, USA), respectively. NKG2D
expression on murine NK cells was assessed with a rat
anti-mouse NKG2D mAb (R&D Systems), revealed by a
FITC-conjugated mouse anti-rat IgG whole molecule mAb
(Sigma-Aldrich). Specificity of the homodimeric proteins
(scFv 511)-Fc and (scFv 4D5)-Fc for CEA and HER2,
respectively, was assessed as follows: tumor cells (5 " 105)
were incubated with each of the two proteins for 1 h at 48C,
washed and then incubated with a FITC-conjugated goat
anti-human IgG Fc specific mAb for 45 min at 48C. Washed
cells were finally analyzed on a FACScan (Becton
Dickinson, San Jose, CA, USA). Capacity of the bifunctional
proteins (scFv 511/rH60)-Fc and (scFv 4D5/rH60)-Fc to coat
tumor cells with H60 was assessed as follows: tumor cells
were first incubated with each of the two proteins for 1 h at
48C, washed and then incubated with a rat anti-H60 mAb for
1 h at 48C, washed and finally detected with a
FITC-conjugated mouse anti-rat IgG2a Fc specific mAb. As
controls, cells were first incubated with the parental homodi-
meric proteins, i.e. rH60-Fc and (scFv 511)-Fc or (scFv
4D5)-Fc, washed, then incubated with a rat anti-H60 mAb
for 1 h at 48C, washed and finally incubated with a
FITC-conjugated mouse anti-rat IgG2a Fc specific mAb for
45 min at 48C, or the cells were incubated with the different
secondary antibodies. Washed cells were similarly analyzed
on a FACScan.
Murine natural killer cells preparation
Murine NK cells used as effectors in chromium release
assays were prepared from a C57BL/6 spleen. Briefly, spleen
was dilacerated, aggregates were eliminated on a 30 mm filter
(Miltenyi Biotec, Auburn, CA, USA) and splenic cells were
cultured for 5 days in DMEM/F12 (1/1) supplemented with
2 mmol/l L-glutamine, 10% FCS, penicillin (100 units/ml)/
streptomycin (100 mg/ml), non-essential amino acids,
1 mmol/L sodium pyruvate (Life Technologies), 50 mmol/L
b-mercaptoethanol and recombinant human interleukin-2
(5000 units/ml) (Proleukin, Chiron, Emeryville, CA, USA).
After 5 days, adherent cells, corresponding to lymphokine
activated killer (LAK) cells were recovered and used as
effectors in chromium release assays.
Chromium-release assays
NK cell-mediated cytotoxicity was measured by the chro-
mium release assay. Tumor target cells (2 " 105 in 100 ml)
were co-incubated for 1 h at 378C with, at the same time,
100 mCi of 51Cr and 5 mg, or less if specified, of the studied
bifunctional protein or antibody. After washing, the labeled
tumor target cells were plated in a 96-well plate (2000 cells
per well) and incubated with LAK cells at different
effector-to-target cell ratios (E:T ratios). For the comparison
of trastuzumab antibody with our anti-HER2 bifunctional
protein, an E:T ratio of 30:1 was used. After incubation for
4 h at 378C, 100 ml of supernatant was taken to measure the
amount of 51Cr released, reflecting the number of target cells
Fig. 1. Schematic representation of the different homodimeric and bifunctional proteins produced. Upper illustrations represent the parental homodimeric
proteins (scFv 511)-Fc, rH60-Fc and (scFv 4D5)-Fc. Lower illustrations represent the two bifunctional proteins obtained after knob and hole variants
generation, namely (scFv 511/rH60)-Fc and (scFv 4D5/rH60)-Fc.
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killed by LAK cells. Spontaneous release of 51Cr was
determined by incubating the target cells with medium
alone. Maximum release was determined by adding 0.1 M
HCl. The percentage of specific lysis was calculated as:
100" [(experimental 2 spontaneous release)/(total2 spon-
taneous release)] (Ogg et al., 2000). In control experiments,
51Cr-labeled tumor target cells were pre-incubated without
any bifunctional protein, with the irrelevant bifunctional
protein, or with the parental homodimeric protein scFv-Fc,
and tested with LAK cells pre-incubated or not for 30 min at
room temperature with a rat anti-mouse NKG2D mAb used
at 20 mg/ml. In the experiment comparing trastuzumab anti-
body and anti-HER2 bifunctional protein, the spontaneous
lysis of SK-BR-3 cells alone was subtracted to each value. In
a reverse antibody-dependent cell-mediated cytotoxicity lysis
assay, THP-1 cells were incubated with 100 mCi of 51Cr
and rH60-Fc, after or without pre-incubation with an FcR
blocking reagent which is composed of intact rat IgG2
antibodies (Miltenyi Biotec), to prevent rH60-Fc binding to
the Fc receptors expressed on THP-1 cells. They were then
incubated with LAK cells.
Results
Production of bifunctional proteins
Supernatants of several G418-resistant HEK 293 clones,
expressing the soluble homodimeric and bifunctional proteins
designed (Fig. 1), were analysed by western blot to identify
the ones producing the attempted proteins in terms of mol-
ecular weight (MW). Production supernatant batches for five
different selected clones were purified on protein G columns,
followed by a gel filtration chromatography.
When loaded on a SDS–PAGE gel under non-reducing
conditions, purified (scFv 4D5/rH60)-Fc bifunctional protein
appeared as a single band of #160 kDa, i.e. at an intermedi-
ate MW between the homodimeric rH60-Fc and (scFv
4D5)-Fc proteins, with MW of #180 and 120 kDa, respect-
ively (Fig. 2A, left part of the gel). Under reducing con-
ditions, bifunctional protein appeared as two bands of 90 and
60 kDa, corresponding to the respective MW of the reduced
parental homodimeric proteins, rH60-Fc and (scFv 4D5)-Fc
(Fig. 2A, right part of the gel). Western blot analysis
(Fig. 2B), using an HRP-conjugated goat anti-human IgG Fc
specific mAb (left membrane) and a rat anti-H60 mAb (right
membrane), confirmed that purified bifunctional (scFv 4D5/
rH60)-Fc protein comprises the mouse NKG2D ligand H60
associated by an Fc part to the considered scFv. The same
results were obtained for the purified bifunctional (scFv 511/
rH60)-Fc protein (data not shown).
Functional evaluation of the recombinant
homodimeric proteins
Homodimeric anti-CEA or anti-HER2 scFv-Fc proteins were
tested for their capacity to bind specifically CEA or HER2
on tumor cells by flow cytometry. Using a FITC-conjugated
anti-human IgG Fc specific mAb, an efficient and specific
binding of the two homodimeric proteins (scFv 511)-Fc and
(scFv 4D5)-Fc to MC38 expressing CEA and B16 expressing
HER2 cells, respectively, was obtained (Fig. 3A, right
panels). Flow cytometry signals of similar magnitudes to
those obtained with specific monoclonal antibodies, 511
mAb and trastuzumab, were observed (Fig. 3A, left panels).
Recombinant H60-Fc protein was tested in a reverse
antibody-dependent cell-mediated cytotoxicity (ADCC) lysis
assay for its capacity to induce NK-mediated tumor cell
lysis. In a chromium release assay using NKG2D-expressing
IL-2 activated murine NK cells (LAK cells) as effectors
(Fig. 3B), pre-incubation of THP-1 cells, which are known
to express FcRs, with rH60-Fc induced a specific increase
of THP-1 cells lysis (Fig. 3C, black bars). This lysis was
reduced to background level (Fig. 3C, white bars) when
THP-1 cells were pre-incubated with an FcR blocking
reagent (Fig. 3C, hatched bars), confirming that this lysis
was exclusively triggered by the coating of these cells
with H60.
Fig. 2. SDS–PAGE and western blot analyses of the bifunctional protein
(scFv 4D5/rH60)-Fc, in comparison with the two parental homodimeric
proteins rH60-Fc and (scFv 4D5)-Fc. (A) SDS–PAGE analysis. Under
non-reducing conditions (left part of the gel) (scFv 4D5/rH60)-Fc appeared
as a single band of intermediate MW compared with the bands obtained for
rH60-Fc and (scFv 4D5)-Fc. Under reducing conditions (right part of the
gel) (scFv 4D5/rH60)-Fc appeared as two bands, each one of MW similar to
the single bands obtained for the two related homodimeric parental proteins.
(B) Western blot analysis. Left membrane, revealed by an HRP-conjugated
goat anti-human IgG Fc specific mAb, confirmed that these two different
chains contain a human Fc part, and that only one (the heavier) contains
H60, as demonstrated in right membrane, first incubated with a rat anti-H60
mAb and then revealed by an HRP-conjugated goat anti-rat IgG whole
molecule mAb. Similar profiles were obtained for (scFv 511/rH60)-Fc
SDS–PAGE and western blot analyses.
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TAA binding capacity of the bifunctional proteins
Binding capacity of the two purified bifunctional proteins to
tumor cells expressing relevant antigens was assessed by
flow cytometry. MC38 cells expressing CEA and B16 cells
expressing HER2 (Fig. 4, first column) did not express
endogenous H60, as assayed with a rat anti-H60 mAb
(Fig. 4, second column). These two cell lines clearly became
positive for H60 detection when incubated with the relevant
bifunctional protein, (scFv 511/rH60)-Fc for MC38-CEAþ
cells and (scFv 4D5/rH60)-Fc for B16-HER2þ cells (Fig. 4,
fifth column). In contrast, no detection of this ligand could
be observed when tumor cells were first incubated with the
different homodimeric proteins (Fig. 4, third and fourth
column), neither when tumor cells were first incubated with
the irrelevant bifunctional protein (data not shown). These
results thus clearly demonstrate the capacity of these two
bifunctional proteins to specifically bind and coat tumor cell
lines expressing CEA or HER2 with H60.
Cytotoxicity assays
Among all the cell lines negative for endogenous H60
expression tested (the human, LS174T, LoVo and HT29
colon carcinomas; SK-BR-3 breast carcinoma; SK-OV-3
ovarian carcinoma, and the murine, MC38 colon carcinoma;
RMA T lymphoma, both transfected with CEA), SK-BR-3
expressing HER2 and CEA-transfected RMA cells (Fig. 5A,
black-filled peaks) were chosen for their high resistance to
lysis mediated by NK cells. Lysis of these two tumor cell
lines was evaluated in the presence of the different bifunc-
tional and control proteins (Fig. 5B–D). In the presence of
the (scFv 4D5/rH60)-Fc bifunctional protein, SK-BR-3 cells
were much more lysed by murine-activated NK cells
(Fig. 5B, black bars). In contrast, no increase of SK-BR-3
cells lysis was observed when these cells, which do not
express CEA (Fig. 5A, left panel, black-dotted peak), were
incubated with the irrelevant bifunctional protein (scFv 511/
rH60)-Fc (Fig. 5B, dark grey bars), neither in presence of the
homodimeric protein (scFv 4D5)-Fc (Fig. 5B, light grey
bars), excluding any Fc receptor-engagement by the Fc part
of the protein and so any antibody-dependent cell cytotox-
icity (ADCC). Similarly, (scFv 511/rH60)-Fc bifunctional
protein significantly sensitized RMA cells expressing CEA
antigen to lysis by activated murine NK cells (Fig. 5D, black
bars). Finally, specific lysis induced by the two bifunctional
proteins studied was abrogated by pre-incubation of murine
NK cells with an anti-mouse NKG2D antibody (Fig. 5B and
D, hatched bars). This clearly demonstrated that the increase
in NK cell-mediated lysis was only the result of H60 engage-
ment, brought exogenously thanks to these two bifunctional
proteins, by the activating receptor NKG2D present on NK
cells. Moreover, stimulation of NKG2D by our anti-HER2
(scFv 4D5/rH60)-Fc bifunctional protein seems to be more
efficient than activation of Fc receptors by anti-HER2 trastu-
zumab antibody to induce NK-mediated SK-BR-3 tumor cell
lysis, whatever the dose tested (Fig. 5C).
Discussion
The in vivo rejection of several types of tumor cells has
been previously described when these ones are genetically
manipulated to express at the cell surface ligands of
NKG2D, an activating receptor expressed on NK and T cells
(Cerwenka et al., 2001; Diefenbach et al., 2001; Friese et al.,
2003; Oppenheim et al., 2005; Busche et al., 2006).
In this study, we designed and purified new bifunctional
proteins, associating a ligand of NKG2D to anti-tumor anti-
body fragments, and demonstrated their capacity to specifi-
cally coat this ligand on different tumor cells and, more
importantly, to induce their lysis by NK cells. Here, actually,
we demonstrate that the exogenous coating of tumor cells
with NKG2D ligands by our bifunctional proteins can induce
Fig. 3. Functional evaluation of the three homodimeric parental molecules.
(A) Flow cytometry evaluation of the control molecules (scFv 511)-Fc and
(scFv 4D5)-Fc on CEA expressing MC38 cells and HER2 expressing B16
cells. Cells were first incubated with scFv-Fc proteins, then with a
FITC-conjugated goat anti-human IgG Fc specific mAb and finally analysed
on a FACScan. Each scFv-Fc protein efficiently bound the TAA considered
(black-filled peaks, right panels). As control, CEA expression on
MC38-CEA cells and HER2 expression on B16-HER2 cells (black filled
peaks, left panels) were evaluated using the specific monoclonal antibodies
511 mAb and trastuzumab, respectively. Cells were first incubated with
monoclonal antibodies, then with a FITC-conjugated goat anti-mouse IgG
Fc specific mAb or with a FITC-conjugated goat anti-human IgG Fc specific
mAb, respectively and finally analysed on a FACScan. (B) NKG2D
expression on murine LAK cells. Cells were first incubated with a rat
anti-mouse NKG2D mAb, then with a FITC-conjugated mouse anti-rat IgG
whole molecule mAb and finally analysed on a FACScan. LAK cells,
obtained after incubation of murine splenocytes for 5 days in presence of
rhIL-2 (5000 units/ml), significantly expressed NKG2D (black-filled peak).
(C) Chromium release evaluation of the control homodimeric rH60-Fc.
Pre-incubation of THP-1 cells with rH60-Fc (black bars) significantly
increased targets specific lysis by murine LAK cells in comparison with
control THP-1 cells (white bars). Addition of an FcR blocking reagent
reduced targets specific lysis to control (hatched bars).
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Fig. 4. Flow cytometry evaluation of the two bifunctional proteins produced. CEA, HER2 and H60 expressions on tumor cells were evaluated using anti-CEA
511 mAb, anti-HER2 trastuzumab or a rat anti-H60 mAb, revealed by a FITC-conjugated goat anti-mouse IgG Fc specific mAb, a FITC conjugated goat
anti-human IgG Fc specific mAb or a FITC conjugated mouse anti-rat IgG2a Fc specific mAb, respectively. Neither CEA expressing MC38 cells nor HER2
expressing B16 cells (black-filled peaks, first column) did express H60 (black-filled peaks, second column). In a second time, tumor cells were first incubated
with the homodimeric parental proteins, rH60-Fc, (scFv 511)-Fc or (scFv 4D5)-Fc, or with the relevant bifunctional molecule, (scFv 511/rH60)-Fc or (scFv
4D5/rH60)-Fc, then with a rat anti-H60 mAb and finally with a FITC-conjugated mouse anti-rat IgG2a Fc specific mAb. As opposed to control molecules
(black-filled peaks, third and fourth columns), each bifunctional molecule specifically coated tumor cells with H60 (black-filled peaks, fifth column).
Fig. 5. Antigenic profile and susceptibility to LAK cells lysis, without and with recombinant bifunctional proteins (scFv anti-TAA/rH60)-Fc, of the different
tumor cell lines tested. (A) CEA, HER2 and H60 expressions on SK-BR-3 and CEA transfected RMA cell lines. Neither HER2 expressing SK-BR-3 cells nor
CEA expressing RMA cells (black-filled peaks) did express H60 (black-thick peaks). SK-BR-3 cells neither expressed CEA (black-dotted peak). (B–D)
Functional evaluation in chromium release assay of the bifunctional proteins (scFv 4D5/rH60)-Fc and (scFv 511/rH60)-Fc. (B) Pre-incubation of SK-BR-3
cells with (scFv 4D5/rH60)-Fc (black bars) significantly increased targets lysis by murine LAK cells in comparison with SK-BR-3 alone (white bars), as
opposed to SK-BR-3 cells pre-incubated with the homodimeric parental protein (scFv 4D5)-Fc (light grey bars) or with the irrelevant bifunctional protein
(scFv 511/rH60)-Fc (dark grey bars). (C) Higher cytotoxicity is obtained when SK-BR-3 cells are pre-incubated with (scFv 4D5/rH60)-Fc (black bars) than
with Herceptin (traztuzumab; white bars) at every doses tested in presence of murine LAK cells. (D) Pre-incubation of RMA-CEA cells with the bifunctional
protein (scFv 4D5/rH60)-Fc (black bars) significantly sensitized targets to lysis by murine LAK cells in comparison with control (white bars). Pre-incubation
of murine LAK cells with a rat anti-mouse NKG2D mAb completely prevented tumor cell lysis increase induced by the bifunctional protein considered (B, D
hatched bars).
C.Germain et al.
670
an efficient and specific NK-mediated lysis of these cells, in
an NKG2D-dependent pathway.
Bispecific antibodies and bifunctional molecules have
been largely exploited in cancer immunotherapy (Koelemij
et al., 1999; Peipp and Valerius, 2002; Kontermann, 2005),
notably in order to favor the recruitment and/or the activation
of effector cells to the tumoral site, by immuno-targeted
cytokines (Gillies et al., 1991; Hoogenboom et al., 1991) or
agonist antibodies against activating receptors expressed on
cytotoxic cells (Van Dijk et al., 1989), thanks to antibody
structures specific for TAAs. Many strategies have been
developed to this aim, such as hybrid hybridomas [quadro-
mas (Milstein and Cuello, 1983)] or chemical conjugation
(Karpovsky et al., 1984; Robert et al., 1996). Nevertheless,
production of this type of molecules is frequently limited in
terms of quality and/or quantity, two major criteria for their
use in humans as therapeutic agents. While quadroma
method leads to the formation of many different contaminant
forms [up to nine (Carter, 2001)] via uncertain rearrangement
of the two heavy chains and the two light chains in presence,
chemical conjugation, using for example Fab’ fragments of
monoclonal antibodies (Robert et al., 1999), is often associ-
ated with poor production outputs. Genetic engineering
allowed the development of other formats such as diabody
(Arndt et al., 1999), single-chain bispecific antibody (Loffler
et al., 2000) or single-chain diabody, but unfortunately fre-
quently associated with short half-lives in vivo (Kontermann,
2005). To bypass this last point, however, an original study
recently proposed the fusion of these small molecules with
human serum albumin, strongly improving their pharmacoki-
netic properties (Muller et al., 2007).
In a previous study (Germain et al., 2005), we demon-
strated the ability of chemical conjugates associating recom-
binant MICA molecules with Fab’ fragments of different
monoclonal anti-tumor antibodies to specifically bind TAAs
and to stimulate NKG2D-dependent lysis of resistant tumor
cells by human NK cells. In the same way, an antitumor
activity against human myeloma has been described with a
recombinant ULBP2-scFv anti CD138 molecule (von
Strandmann et al., 2006). Here, in the perspective to produce
higher amounts of in vivo usable bifunctional proteins, we
chose to use the ‘knob into hole’ strategy, which was devel-
oped to produce bispecific antibodies easily purified from
culture supernatant (Ridgway et al., 1996; Merchant et al.,
1998), based on the preferential heterodimerization of two
distinct heavy chains of human immunoglobulin. Recently,
Xie et al. applied similarly this technology for the production
of a bispecific antibody associating an anti-HER2 scFv to an
anti-CD16 scFv to stimulate in vitro CD16-dependent tumor
cell lysis by PBMC (Xie et al., 2005). In contrast to this
report, the (scFv anti-TAA)/rH60-Fc bifunctional proteins
produced here associate an anti-tumor scFv to a recombinant
form of one of the natural ligands of the mouse NKG2D
receptor, H60, able as shown for MICA in humans to induce
mouse NK cells cytotoxicity when expressed on tumor cells
(Cerwenka et al., 2000; Diefenbach et al., 2000). We postu-
lated that the intermediate affinity of H60 for mouse
NKG2D, compared with other mouse NKG2D ligands
(O’Callaghan et al., 2001; Carayannopoulos et al., 2002), is
high enough to bind and activate NK cells when coated
on tumor cells, in correlation with TAA expression degree,
and not sufficiently high to induce a dramatic, or ineffective,
NK cell activation in the whole blood circulation. This
hypothesis is supported by results previously obtained during
the evaluation of the ability of Fab-HLA-A2/Flu conjugates
to activate T-lymphocytes, in soluble form or coated on
tumor cells (Robert et al., 2001). Using Ca2
þ mobilization
assays, we demonstrated that these conjugates, associating
monomeric HLA-A2/Flu complexes to anti-TAA Fab’ frag-
ments, can efficiently activate CTL only when oligomerized
on the surface of tumor cells.
In the present study, we demonstrated that the two pro-
duced (scFv anti-TAA)/rH60-Fc bifunctional proteins are
able to specifically coat CEA- or HER2-expressing tumor
cells with H60, and to induce their lysis by mouse-activated
NK cells in an NKG2D-dependent manner.
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